ArticleJHEP reports : innovation in hepatology2022
Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event.
Article in JHEP reports : innovation in hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 51 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Low-Dose vs. Standard Care Iv Human Albumin During Large-Volume Paracentesis in Patients With Liver Cirrhosis: A Systematic Review.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- EASL position paper on palliative care in advanced chronic liver disease.JHEP reports : innovation in hepatology · 2026Guideline
- Sodium-Glucose Cotransporter-2 Inhibitors in Liver Cirrhosis: A Systematic Review of Their Role in Ascites Management, Slowing Disease Progression, and Safety.International journal of molecular sciences · 2025Pooled it
- CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PORTAL HYPERTENSION.Acta clinica Croatica · 2024Guideline
- A multicenter multistate modeling on the natural history of liver decompensation: Longitudinal analysis of 1777 patients.Hepatology communications · 2026Article
- From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD.International journal of molecular sciences · 2026Review
- AI-assisted ascites volumetry for prognostic stratification in HCC treated with Atezolizumab/Bevacizumab.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Reply to: "External validation of a simple risk stratification for portal hypertension-related clinical deterioration in patients with ascites".JHEP reports : innovation in hepatology · 2026Article
- Epidemiology of Patients With Chronic Liver Disease Presenting to Emergency Departments in Australia.Emergency medicine Australasia : EMA · 2026Article
- Characterization of liver disease regression in murine models of liver fibrosis and portal hypertension.Scientific reports · 2026Article
- Unstable Recompensation: An Intermediate Subtype in Patients With HBV-Related Decompensated Cirrhosis.Alimentary pharmacology & therapeutics · 2026Article
- Alcohol Use After TIPS Implantation Significantly Increases the Risk of ACLF and Liver-Related Death.United European gastroenterology journal · 2026Article
- Splanchnic hemodynamic parameters measured with 4D flow MRI can diagnose severe portal hypertension.European radiology · 2026Article
- A Delphi Study on the Development of a Traditional Chinese Medicine Syndrome-Differentiation Nursing Framework for Patients with Cirrhotic Ascites.Journal of multidisciplinary healthcare · 2026Article
- Peri-transplant use of immune checkpoint inhibitors in hepatocellular carcinoma: a transplant oncology perspective on safety, timing, post-transplant management, and future directions.Frontiers in oncology · 2026Review
- Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non-Acute Decompensation.Alimentary pharmacology & therapeutics · 2025Observational
- Integrating prior decompensation into ACLF definition to enhance clinical management.Hepatology international · 2025Article
- Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study.World journal of hepatology · 2025Article
- [Clinical outcomes of small-size grafts in auxiliary liver transplantation for the treatment of portal hypertension].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Reply to: "Predicting the need for early TIPS in patients with cirrhosis and ascites: More art than science".JHEP reports : innovation in hepatology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Although ascites is the most frequent first decompensating event in cirrhosis, the clinical course after ascites as the Methods: A total of 622 patients with cirrhosis presenting with grade 2/3 ascites as the Results: The mean age was 57 ± 11 years, and most patients were male (n = 423, 68%) with alcohol-related (n = 366, 59%) and viral (n = 200,32%) liver disease as the main aetiologies. In total, 323 (52%) patients presented with grade 2 and 299 (48%) with grade 3 ascites. The median Child-Pugh score at presentation was 8 (IQR 7-9), and the mean model for end-stage liver disease (MELD) was 15 ± 6. During a median follow-up period of 49 months, 350 (56%) patients experienced further decompensation: refractory ascites (n = 130, 21%), hepatic encephalopathy (n = 112, 18%), spontaneous bacterial peritonitis (n = 32, 5%), hepatorenal syndrome-acute kidney injury (n = 29, 5%). Variceal bleeding as an isolated further decompensation event was rare (n = 18, 3%), whereas non-bleeding further decompensation (n = 161, 26%) and ≥2 concomitant further decompensation events (n = 171, 27%) were frequent. Transjugular intrahepatic portosystemic shunt was used in only 81 (13%) patients. In patients presenting with grade 2 ascites, MELD ≥15 indicated a considerable risk for further decompensation (subdistribution hazard ratio [SHR] 2.18; Conclusions: Further decompensation is frequent in patients with ascites as a Lay summary: Decompensation (the development of symptoms as a result of worsening liver function) marks a turning point in the disease course for patients with cirrhosis. Ascites (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.